title,date,content,tickers,image,link,author,site
Broadcom Soars 7% on Strong AI Chip Demand and Upbeat Guidance,2025-03-07 11:45:00,"<p><a href='https://financialmodelingprep.com/financial-summary/AVGO'>Broadcom (NASDAQ:AVGO)</a> surged more than 7% intra-day today after posting robust fiscal first-quarter earnings and issuing an optimistic outlook for the current quarter, driven by sustained demand for its AI chips.</p>
<p>The semiconductor giant has benefited from a growing shift among major cloud providers seeking alternatives to Nvidia, whose supply constraints have pushed tech titans like Microsoft and Amazon to explore Broadcom and its peer Marvell for AI chip solutions. Broadcom’s custom AI chips are helping large-scale language models process vast amounts of data at higher speeds, making them an attractive option for cloud computing firms.</p>
<p>For the quarter, Broadcom reported adjusted earnings per share of $1.60 on revenue of $14.92 billion, beating analyst estimates of $1.51 EPS and $14.59 billion in revenue. AI-related revenue surged 77% year-over-year to $4.1 billion, reinforcing its position as a key player in the AI-driven semiconductor space.</p>
<p>Broadcom’s core semiconductor solutions business posted a 55% increase, generating $8.2 billion, while its infrastructure software division also performed well, growing 45% to $6.7 billion.</p>
<p>The company also delivered strong guidance for its fiscal second quarter, projecting revenue of $14.9 billion, surpassing market expectations of $14.73 billion. </p>
",NASDAQ:AVGO,https://cdn.financialmodelingprep.com/images/fmp-1741365903440.jpg,https://financialmodelingprep.com/market-news/fmp-broadcom-soars-7-on-strong-ai-chip-demand-and-upbeat-guidance,Davit Kirakosyan,Financial Modeling Prep
Costco Beats Revenue Expectations but Falls Short on Profit in Q2,2025-03-07 11:40:00,"<p><a href='https://financialmodelingprep.com/financial-summary/COST'>Costco (NASDAQ:COST)</a> reported mixed fiscal second-quarter results, as revenue topped estimates while earnings came in below expectations. The warehouse retailer saw strong consumer demand, driven by inflation concerns and bulk-buying trends, but margin pressures weighed on profitability. Shares dropped more than 6% intra-day today following the report.</p>
<p>Costco posted quarterly earnings per diluted share of $4.02, missing analyst expectations of $4.11. However, revenue came in at $63.72 billion, surpassing the forecasted $63.08 billion.</p>
<p>Comparable sales, which account for fluctuations in gas prices and foreign currency, rose 6.8% year-over-year. Additionally, membership fees climbed 7.4% to $1.19 billion, slightly below the estimated $1.22 billion but still reflecting solid customer retention and growth.</p>
<p>Despite the revenue beat, Costco faced pressure on its gross margins due to rising input costs. Egg prices have surged as U.S. bird flu outbreaks impact supply, while increases in cocoa and coffee prices have added further cost pressures.</p>
<p>Although Costco remains a strong player in the retail sector, investors reacted cautiously to the earnings miss and the lingering inflationary concerns affecting margins.</p>
",NASDAQ:COST,https://cdn.financialmodelingprep.com/images/fmp-1741365652912.jpg,https://financialmodelingprep.com/market-news/fmp-costco-beats-revenue-expectations-but-falls-short-on-profit-in-q2,Davit Kirakosyan,Financial Modeling Prep
HPE Shares Plunge 15% as Weak Guidance and Margin Pressure Weigh on Results,2025-03-07 11:36:00,"<p><a href='https://financialmodelingprep.com/financial-summary/HPE'>Hewlett Packard Enterprise (NYSE:HPE)</a> saw its shares tumble over 15% intra-day today after delivering a mixed fiscal first-quarter report and issuing weaker-than-expected guidance. The company also announced job cuts, adding to investor concerns.</p>
<p>For the quarter, HPE posted adjusted earnings per share (EPS) of $0.49, narrowly missing Wall Street estimates of $0.50. However, revenue came in at $7.85 billion, slightly surpassing the consensus estimate of $7.81 billion and marking a 16% year-over-year increase.</p>
<p>CEO Antonio Neri highlighted that the company achieved its fourth consecutive quarter of year-over-year revenue growth, with double-digit gains in Q1. Despite this, profitability took a hit, as non-GAAP gross margin fell 680 basis points year-over-year to 29.4%.</p>
<p>HPE’s outlook significantly dampened investor sentiment. The company expects second-quarter adjusted EPS in the range of $0.28-$0.34, far below the analyst consensus of $0.50. Revenue guidance of $7.2-$7.6 billion also missed expectations of $7.93 billion.</p>
<p>For the full fiscal year 2025, HPE forecasted adjusted EPS of $1.70-$1.90, trailing Wall Street’s projection of $2.13. Revenue is projected to grow by 7-11% in constant currency, while non-GAAP operating profit growth is expected to range between -10% and 0%.</p>
<p>Adding to the disappointment, HPE provided an operating margin forecast of around 9% at the midpoint, falling short of the 10.7% consensus estimate. With weaker earnings projections and ongoing margin compression, the market reacted sharply, leading to a steep sell-off in HPE shares.</p>
",NYSE:HPE,https://cdn.financialmodelingprep.com/images/fmp-1741365398549.jpg,https://financialmodelingprep.com/market-news/fmp-hpe-shares-plunge-15-as-weak-guidance-and-margin-pressure-weigh-on-results,Davit Kirakosyan,Financial Modeling Prep
"Samsara Drops 13% Despite Strong Q4 Earnings Beat, Guidance Weighs on Shares",2025-03-07 11:28:00,"<p><a href='https://financialmodelingprep.com/financial-summary/IOT'>Samsara (NYSE:IOT)</a> saw its shares plunge over 13% intra-day today, as investors reacted negatively to its forward guidance, despite the company delivering fourth-quarter results that topped expectations.</p>
<p>The company reported adjusted earnings per share of $0.11, surpassing analyst projections of $0.07. Revenue climbed 25% year-over-year to $346.3 million, beating the consensus estimate of $335.35 million.</p>
<p>For the first quarter of fiscal 2026, Samsara guided EPS between $0.05 and $0.06, in line with analysts' expectations of $0.05. Revenue is projected between $350 million and $352 million, aligning closely with the consensus estimate of $351.3 million.</p>
<p>The company’s full-year outlook showed a mixed picture. Samsara expects EPS in the range of $0.32 to $0.34, above the consensus estimate of $0.28. However, revenue guidance of $1.523 billion to $1.533 billion fell slightly short of the $1.528 billion midpoint expected by analysts.</p>
<p>CEO Sanjit Biswas highlighted another year of strong growth, noting that Samsara ended fiscal 2025 with annual recurring revenue (ARR) of $1.458 billion, a 32% increase from the prior year. The company also reported 2,506 customers with ARR over $100,000, marking a 36% year-over-year rise.</p>
",NYSE:IOT,https://cdn.financialmodelingprep.com/images/fmp-1741364905509.jpg,https://financialmodelingprep.com/market-news/fmp-samsara-drops-13-despite-strong-q4-earnings-beat-guidance-weighs-on-shares,Davit Kirakosyan,Financial Modeling Prep
Gap Soars 14% on Strong Q4 Earnings Beat and Dividend Hike,2025-03-07 11:24:00,"<p><a href='https://financialmodelingprep.com/financial-summary/GAP'>Gap (NYSE:GAP)</a> surged over 14% intra-day today after delivering fourth-quarter earnings and revenue that exceeded expectations. The apparel retailer also boosted investor confidence by announcing a 10% increase in its quarterly dividend.</p>
<p>For the quarter, Gap reported adjusted earnings per share (EPS) of $0.54, significantly outpacing analyst estimates of $0.36. Revenue reached $4.1 billion, slightly surpassing the consensus forecast of $4.07 billion. Comparable sales increased 3% year-over-year, reinforcing the company’s steady growth.</p>
<p>CEO Richard Dickson highlighted that Gap not only outperformed financial expectations but also gained market share for the eighth consecutive quarter.</p>
<p>For the full year 2024, Gap posted net sales of $15.1 billion, marking a 1% increase from the prior year. Comparable sales also rose 3%, while operating income surged over 80% year-over-year to $1.1 billion.</p>
<p>Looking ahead, the company projects net sales growth of 1% to 2% for fiscal 2025, with operating income expected to rise between 8% and 10%. For the first quarter of 2025, Gap anticipates flat to slightly positive sales growth compared to Q1 2024.</p>
",NYSE:GAP,https://cdn.financialmodelingprep.com/images/fmp-1741364696547.jpg,https://financialmodelingprep.com/market-news/fmp-gap-soars-14-on-strong-q4-earnings-beat-and-dividend-hike,Davit Kirakosyan,Financial Modeling Prep
Best Buy Maintained With Buy Rating as Product Cycle and Margin Growth Drive Optimism,2025-03-07 11:20:00,"<p>DA Davidson analysts reaffirmed a Buy rating and a $110.00 price target on <a href='https://financialmodelingprep.com/financial-summary/BBY'>Best Buy (NYSE:BBY)</a>, citing strong fourth-quarter performance and promising growth trends.</p>
<p>The analysts highlighted that Best Buy’s Q4 comparable sales beat indicates the early stages of a product cycle ramp, which began in computing and is expected to extend into other categories throughout the year. </p>
<p>However, the analysts also noted emerging risks related to tariffs, as a significant portion of Best Buy’s product inventory is manufactured overseas. While tariffs were not explicitly included in the company’s guidance, they could pose a headwind to future results if trade policies shift.</p>
<p>Despite these concerns, the analysts remain optimistic about Best Buy’s growth trajectory, supported by strengthening product demand and ongoing margin expansion.</p>
",NYSE:BBY,https://cdn.financialmodelingprep.com/images/fmp-1741364451616.jpg,https://financialmodelingprep.com/market-news/fmp-best-buy-maintained-with-buy-rating-as-product-cycle-and-margin-growth-drive-optimism,Davit Kirakosyan,Financial Modeling Prep
DarioHealth Corp. (NASDAQ:DRIO) Earnings Preview: A Deep Dive into Financial Health and Market Position,2025-03-07 09:00:02,"<ul>
<li><strong>Anticipated quarterly loss</strong> of $0.16 per share with projected revenue of $7.39 million.</li>
<li><strong>Negative P/E ratio</strong> of -0.85, yet a positive price-to-sales ratio of 1.31 reflects investor confidence.</li>
<li><strong>Financial metrics</strong> reveal challenges in cash flow but indicate sufficient liquidity and manageable debt levels.</li>
</ul>

<p><a href=""https://site.financialmodelingprep.com/financial-summary/DRIO"">DarioHealth Corp. (NASDAQ:DRIO)</a> is a key player in the <strong>digital health sector</strong>, focusing on innovative solutions for chronic disease management. As the company prepares to release its quarterly earnings on March 10, 2025, Wall Street anticipates a loss of <strong>$0.16 per share</strong>. Revenue is projected to be around <strong>$7.39 million</strong>, reflecting the company's ongoing efforts in the competitive digital health market.</p>

<p>The upcoming earnings call will be led by CEO Erez Raphael and Chief Commercial Officer Steven Nelson. This event will provide insights into the company's financial health and strategic direction. Despite a negative price-to-earnings (P/E) ratio of <strong>-0.85</strong>, DRIO remains a significant player in its industry, with a price-to-sales ratio of <strong>1.31</strong>, indicating investor confidence in its sales potential.</p>

<p>DRIO's enterprise value to sales ratio is approximately <strong>1.96</strong>, suggesting a valuation that considers both debt and equity relative to sales. However, the enterprise value to operating cash flow ratio of <strong>-1.15</strong> highlights challenges in generating positive cash flow. The earnings yield of <strong>-1.18%</strong> further underscores the company's current earnings difficulties.</p>

<p>The company's debt-to-equity ratio of <strong>0.52</strong> indicates a moderate level of debt compared to equity, which is manageable. Additionally, a current ratio of <strong>1.57</strong> suggests that DRIO has sufficient liquidity to meet its short-term obligations. These financial metrics provide a comprehensive view of DRIO's financial standing as it approaches its earnings release.</p>",NASDAQ:DRIO,https://portal.financialmodelingprep.com/positions/67cafd563b1fda08ff03f605.jpeg,https://financialmodelingprep.com/market-news/dariohealth-corp-drio-earnings-preview-financial-health-market-position,Tony Dante,Financial Modeling Prep
"Neuronetics, Inc. (NASDAQ:STIM) Financial Efficiency Analysis",2025-03-07 07:00:07,"<p>Neuronetics, Inc. (<a href=""https://site.financialmodelingprep.com/financial-summary/STIM"">NASDAQ:STIM</a>) is a leading medical technology company that specializes in developing non-invasive treatments for psychiatric disorders, notably through its NeuroStar Advanced Therapy System for transcranial magnetic stimulation (TMS) to treat major depressive disorder.</p>
<p>Operating in a competitive landscape, Neuronetics faces stiff competition from companies like Kezar Life Sciences, Scholar Rock Holding Corporation, Verrica Pharmaceuticals, SI-BONE, and Sutro Biopharma.</p>
<p>In assessing Neuronetics' financial efficiency, the <strong>Return on Invested Capital (ROIC)</strong> stands out as a pivotal metric. Neuronetics reports a <strong>ROIC of -32.27%</strong>, significantly underperforming its <strong>Weighted Average Cost of Capital (WACC) of 12.03%</strong>. This discrepancy results in a <strong>ROIC to WACC ratio of -2.68</strong>, signaling that the company is not generating adequate returns to cover its cost of capital.</p>
<p>Comparatively, Kezar Life Sciences exhibits a <strong>ROIC of -64.27%</strong> and a <strong>WACC of 6.37%</strong>, leading to a <strong>ROIC to WACC ratio of -10.10</strong>. This indicates that Kezar is less efficient than Neuronetics in generating returns relative to its cost of capital.</p>
<p>Similarly, Scholar Rock Holding Corporation and Verrica Pharmaceuticals also demonstrate lower efficiency with <strong>ROIC to WACC ratios of -8.56</strong> and <strong>-55.95</strong>, respectively.</p>
<p>SI-BONE, Inc. presents a marginally better scenario with a <strong>ROIC of -17.82%</strong> and a <strong>WACC of 10.01%</strong>, resulting in a <strong>ROIC to WACC ratio of -1.78</strong>. This suggests that SI-BONE is more efficient than Neuronetics, albeit still not generating positive returns. Sutro Biopharma, with a <strong>ROIC to WACC ratio of -1.64</strong>, emerges as the least inefficient among the peers, indicating it is closer to achieving a balance between returns and cost of capital.</p>
<p>Overall, while Neuronetics is not currently generating positive returns on its invested capital, it is relatively more efficient than some of its peers. This comparison underscores the challenges faced by companies in the medical technology and biopharmaceutical sectors in achieving profitability and efficient capital utilization.</p>",NASDAQ:STIM,https://portal.financialmodelingprep.com/positions/67caf9813b1fda08ff03e638.png,https://financialmodelingprep.com/market-news/neuronetics-inc-nasdaq-stim-financial-efficiency-analysis,Andrew Wynn,Financial Modeling Prep
"Theriva Biologics, Inc. (AMEX:TOVX) Financial Analysis and Peer Comparison",2025-03-07 07:00:07,"<p><a href=""https://site.financialmodelingprep.com/financial-summary/TOVX"">Theriva Biologics, Inc. (AMEX:TOVX)</a> is a biotechnology company focused on developing innovative therapies for cancer and other diseases. The company aims to leverage its expertise in biologics to create effective treatments. In the competitive landscape, Theriva faces peers like Imunon, Inc., Fresh Tracks Therapeutics, Inc., LogicMark, Inc., Lisata Therapeutics, Inc., and Eledon Pharmaceuticals, Inc.</p>

<p>Theriva Biologics has a <strong>Return on Invested Capital (ROIC) of -92.88%</strong>, which is significantly lower than its <strong>Weighted Average Cost of Capital (WACC) of 5.46%</strong>. This negative ROIC indicates that the company is not generating positive returns on its invested capital. The <strong>ROIC to WACC ratio of -17.02</strong> further highlights that Theriva's returns are well below its cost of capital, suggesting inefficiencies in capital utilization.</p>

<p>In contrast, Imunon, Inc. (<a href=""https://site.financialmodelingprep.com/financial-summary/IMNN"">IMNN</a>) showcases a remarkable <strong>ROIC of 442.47%</strong> against a <strong>WACC of 3.90%</strong>, resulting in a <strong>ROIC to WACC ratio of 113.58</strong>. This indicates that Imunon is generating returns significantly above its cost of capital, highlighting its strong capital efficiency and potential for growth. This performance sets Imunon apart from its peers in the biotechnology sector.</p>

<p>Fresh Tracks Therapeutics, Inc. (<a href=""https://site.financialmodelingprep.com/financial-summary/FRTX"">FRTX</a>) presents a more balanced scenario with a <strong>ROIC of 3.53%</strong> and a <strong>WACC of 9.55%</strong>, leading to a <strong>ROIC to WACC ratio of 0.37</strong>. Although the returns are below the cost of capital, the gap is not as pronounced as in Theriva's case. This suggests that Fresh Tracks is closer to achieving efficient capital utilization compared to Theriva.</p>

<p>Other peers like LogicMark, Inc. (<a href=""https://site.financialmodelingprep.com/financial-summary/LGMK"">LGMK</a>) and Eledon Pharmaceuticals, Inc. (<a href=""https://site.financialmodelingprep.com/financial-summary/ELDN"">ELDN</a>) also report negative ROICs of <strong>-48.29%</strong> and <strong>-54.51%</strong>, respectively, with ROIC to WACC ratios of <strong>-5.83</strong> and <strong>-6.98</strong>. These figures indicate that these companies, like Theriva, are struggling to generate returns above their cost of capital, pointing to potential challenges in their capital management strategies.</p>",NYSE:TOVX,https://portal.financialmodelingprep.com/positions/67caf9f63b1fda08ff03e951.png,https://financialmodelingprep.com/market-news/theriva-biologics-financial-analysis-peer-comparison,Alex Lavoie,Financial Modeling Prep
"Aytu BioPharma, Inc. (NASDAQ:AYTU) and Its Competitive Landscape",2025-03-07 07:00:05,"<ul>
<li><strong>Aytu BioPharma's</strong> <a href=""https://site.financialmodelingprep.com/financial-summary/AYTU""><strong>Return on Invested Capital (ROIC)</strong></a> is <strong>-18.15%</strong>, indicating inefficiency in using capital to generate profits.</li>
<li>Among its peers, <strong>Co-Diagnostics, Inc.</strong> has the least negative ROIC to WACC ratio, suggesting a relatively better potential for financial improvement.</li>
<li><strong>AIM ImmunoTech Inc.</strong> shows a significantly negative ROIC to WACC ratio of <strong>-78.36</strong>, highlighting its struggle to generate returns.</li>
</ul>

<p><a href=""https://site.financialmodelingprep.com/financial-summary/AYTU"">Aytu BioPharma, Inc. (NASDAQ:AYTU)</a> is a specialty pharmaceutical company focused on commercializing novel therapeutics. The company operates in a competitive landscape with peers like Co-Diagnostics, Inc., AIM ImmunoTech Inc., iBio, Inc., Biocept, Inc., and OpGen, Inc. These companies are also involved in the biotechnology and pharmaceutical sectors, each striving to innovate and capture market share.</p>

<p>Aytu BioPharma's <strong>Return on Invested Capital (ROIC)</strong> is <strong>-18.15%</strong>, while its <strong>Weighted Average Cost of Capital (WACC)</strong> is <strong>23.23%</strong>. This results in a ROIC to WACC ratio of <strong>-0.78</strong>, indicating that the company is not generating enough returns to cover its cost of capital. This is a red flag for investors, as it suggests inefficiency in using its capital to generate profits.</p>

<p>In comparison, Co-Diagnostics, Inc. has a ROIC of <strong>-69.90%</strong> and a WACC of <strong>9.04%</strong>, leading to a ROIC to WACC ratio of <strong>-7.73</strong>. Although still negative, Co-Diagnostics has the least negative ratio among its peers, suggesting it is closer to covering its cost of capital. This could imply a relatively better potential for financial improvement.</p>

<p>AIM ImmunoTech Inc. shows a ROIC of <strong>-451.42%</strong> against a WACC of <strong>5.76%</strong>, resulting in a ROIC to WACC ratio of <strong>-78.36</strong>. This significant negative ratio highlights the company's struggle to generate returns, making it less attractive to investors compared to its peers. Similarly, iBio, Inc. and Biocept, Inc. also exhibit negative ROIC to WACC ratios of <strong>-9.95</strong> and <strong>-26.61</strong>, respectively, indicating challenges in covering their capital costs.</p>

<p>OpGen, Inc. presents a ROIC of <strong>-408.66%</strong> and a WACC of <strong>13.54%</strong>, leading to a ROIC to WACC ratio of <strong>-30.18</strong>. This further emphasizes the difficulties faced by these companies in generating sufficient returns. Investors should carefully consider these financial metrics, as they reflect the companies' current inefficiencies in capital utilization.</p>",NASDAQ:AYTU,https://portal.financialmodelingprep.com/positions/67cafa2a3b1fda08ff03ea94.png,https://financialmodelingprep.com/market-news/aytu-biopharma-nasdaq-aytu-competitive-landscape-analysis,Rayan Ahmad,Financial Modeling Prep
"Tivic Health Systems, Inc. (NASDAQ:TIVC) Executes Reverse Stock Split",2025-03-07 00:00:05,"<ul>
<li><a href=""https://site.financialmodelingprep.com/financial-summary/TIVC"">Tivic Health Systems, Inc. (NASDAQ:TIVC)</a> has conducted a reverse stock split at a ratio of 17 for 1 to meet Nasdaq's minimum bid price requirement.</li>
<li>The current stock price of TIVC reflects a decrease of <strong>12.67%</strong>, indicating significant price volatility over the past year.</li>
<li>TIVC's market capitalization stands at approximately <strong>$2.42 million</strong>, with a trading volume of 894,535 shares on the NASDAQ exchange.</li>
</ul>

<p><a href=""https://site.financialmodelingprep.com/financial-summary/TIVC"">Tivic Health Systems, Inc. (NASDAQ:TIVC)</a> is a company focused on developing and commercializing bioelectronic medicine. It aims to provide non-invasive solutions for various health conditions. TIVC competes in the medical technology sector, where innovation and regulatory compliance are crucial for success. The company recently made a significant financial decision to ensure its continued presence on the Nasdaq Capital Market.</p>

<p>On March 7, 2025, TIVC executed a reverse stock split at a ratio of 17 for 1. This means that for every 17 shares previously held, shareholders now own one share. The reverse stock split is a strategic move to increase the stock price and meet the minimum bid price requirement set by Nasdaq. This decision was made by the Board of Directors to maintain compliance with Nasdaq's listing standards.</p>

<p>The current stock price of TIVC is <strong>$0.2558</strong>, which reflects a decrease of <strong>12.67%</strong> with a change of <strong>$0.0371</strong>. The stock has shown volatility, with today's price fluctuating between a low of $0.2539 and a high of $0.2855. Over the past year, TIVC's stock price has ranged from a high of $31.45 to a low of $0.2513, indicating significant price movement.</p>

<p>TIVC's market capitalization is approximately <strong>$2.42 million</strong>, which is relatively small compared to larger companies in the medical technology sector. The trading volume on the NASDAQ exchange is 894,535 shares, suggesting active trading interest. The reverse stock split is part of the company's efforts to stabilize its stock price and maintain its Nasdaq listing.</p>",NASDAQ:TIVC,https://portal.financialmodelingprep.com/positions/67cafa573b1fda08ff03eb08.jpeg,https://financialmodelingprep.com/market-news/tivic-health-systems-reverse-stock-split-nasdaq-listing,Gordon Thompson,Financial Modeling Prep
Merck KGaA's Financial Overview and Market Position,2025-03-06 20:00:04,"<ul>
<li>Merck KGaA (<a href=""https://site.financialmodelingprep.com/financial-summary/MKGAF"">PNK:MKGAF</a>) reported earnings per share of <strong>$2.14</strong>, missing estimates.</li>
<li>The company's revenue was <strong>$5.61 billion</strong>, slightly below expectations.</li>
<li>Merck projects up to <strong>8%</strong> currency-adjusted operating earnings growth for the year.</li>
</ul>

<p>Merck KGaA, trading under the symbol <a href=""https://site.financialmodelingprep.com/financial-summary/MKGAF"">PNK:MKGAF</a>, is a prominent player in the pharmaceutical and chemical industries. The company operates through various divisions, including Life Science, Healthcare, and Electronics, providing a wide range of products and services. Merck faces competition from other major pharmaceutical companies, but it remains a key player due to its diverse portfolio and strategic initiatives.</p>

<p>On March 6, 2025, Merck reported earnings per share of <strong>$2.14</strong>, which fell short of the estimated <strong>$2.23</strong>. The company's revenue was approximately <strong>$5.61 billion</strong>, slightly below the expected <strong>$5.67 billion</strong>. Despite these figures, Merck's leadership remains optimistic about future growth, as highlighted during their Q4 2024 earnings call. The call featured insights from key figures, including Group CEO Belen Garijo and Group CFO Helene von Roeder, who discussed the company's performance and strategic direction.</p>

<p>Merck has projected a currency-adjusted operating earnings growth of up to <strong>8%</strong> for the year, driven by strong demand for semiconductor chemicals and lab equipment used in biotech drug production. This optimistic forecast reflects the company's confidence in its ability to capitalize on market opportunities and drive growth. The presence of major financial institutions like UBS, J.P. Morgan, Goldman Sachs, Bank of America, and Barclays during the earnings call indicates significant interest from the investment community.</p>

<p>The company's financial metrics provide further insight into its market position. Merck's price-to-earnings (P/E) ratio is approximately <strong>22.49</strong>, indicating the market's valuation of its earnings. Its price-to-sales ratio stands at about <strong>2.89</strong>, reflecting the company's market value relative to its sales. The enterprise value to sales ratio is around <strong>2.74</strong>, suggesting how the company's total value compares to its sales. These figures highlight Merck's strong market presence and potential for growth.</p>

<p>Additionally, Merck's enterprise value to operating cash flow ratio is approximately <strong>13.04</strong>, providing insight into the company's valuation against its cash flow from operations. The earnings yield is about <strong>4.45%</strong>, offering a perspective on the return on investment. Lastly, the current ratio is approximately <strong>1.33</strong>, indicating the company's ability to cover its short-term liabilities with its short-term assets. These financial metrics underscore Merck's solid financial health and ability to navigate market challenges.</p>",PNK:MKGAF,https://portal.financialmodelingprep.com/positions/67cafb8c3b1fda08ff03edee.jpeg,https://financialmodelingprep.com/market-news/merck-kgaa-financial-overview-market-position,Andrew Wynn,Financial Modeling Prep
"KVH Industries, Inc. (NASDAQ: KVHI) Earnings Report Highlights",2025-03-06 19:00:04,"<ul>
<li><strong>Earnings per Share (EPS)</strong> fell short at <strong>-$0.22</strong> compared to the estimated <strong>-$0.07</strong>.</li>
<li>Total revenues decreased by <strong>14%</strong> in Q4 2024 compared to the same period in 2023.</li>
<li>The company showed a significant <strong>20% decline</strong> in airtime revenue, but improved its net loss to <strong>$4.3 million</strong> from <strong>$12.2 million</strong> in Q4 2023.</li>
</ul>

<p><a href=""https://site.financialmodelingprep.com/financial-summary/KVHI"">KVH Industries, Inc. (NASDAQ: KVHI)</a> specializes in mobile connectivity and inertial navigation systems, facing stiff competition in the satellite communications sector. On March 6, 2025, KVHI reported its Q4 2024 financial results, revealing an EPS of <strong>-$0.22</strong> and actual revenue of <strong>$26.9 million</strong>, both slightly below expectations.</p>

<p>During the earnings call, CFO Anthony Pike and CEO Brent Bruun discussed the company's financial performance and strategic direction. A notable point was the <strong>20% decline</strong> in airtime revenue, dropping to <strong>$20.8 million</strong>. However, the net loss improved to <strong>$4.3 million</strong>, or <strong>-$0.22</strong> per share, from a net loss of <strong>$12.2 million</strong>, or <strong>-$0.63</strong> per share, in the previous year.</p>

<p>KVHI's financial metrics indicate challenges, with a negative P/E ratio of <strong>-5.51</strong> and a price-to-sales ratio of approximately <strong>0.90</strong>. The enterprise value to sales ratio is around <strong>0.79</strong>, suggesting the company's valuation is less than its sales. Despite these hurdles, KVHI maintains a strong current ratio of about <strong>5.58</strong> and a very low debt-to-equity ratio of approximately <strong>0.0077</strong>, indicating minimal reliance on debt financing and a robust ability to cover short-term liabilities.</p>",NASDAQ:KVHI,https://portal.financialmodelingprep.com/positions/67cafbc93b1fda08ff03ef5e.jpeg,https://financialmodelingprep.com/market-news/kvh-industries-inc-kvhi-q4-2024-earnings-report-overview,Andrew Wynn,Financial Modeling Prep
SOPHiA GENETICS SA (NASDAQ:SOPH) Financial Analysis,2025-03-06 16:00:06,"<ul>
<li><strong>SOPH's Return on Invested Capital (ROIC)</strong> is -52.00%, indicating it is not generating sufficient returns to cover its cost of capital.</li>
<li>Comparative analysis shows peers like <strong>Rapid Micro Biosystems</strong> and <strong>Singular Genomics Systems</strong> also struggle with negative ROIC against their WACC.</li>
<li><strong>Absci Corporation</strong> has the highest ROIC to WACC ratio among the peers, suggesting a relatively better capital efficiency.</li>
</ul>

<p><a href=""https://site.financialmodelingprep.com/financial-summary/SOPH"">SOPHiA GENETICS SA (NASDAQ:SOPH)</a> is a company that specializes in data-driven medicine, providing a cloud-based platform for healthcare professionals to analyze genomic and radiomic data. This platform aids in the diagnosis and treatment of diseases, making SOPH a key player in the healthcare technology sector. Its competitors include companies like Rapid Micro Biosystems, Singular Genomics Systems, Rallybio Corporation, Absci Corporation, and Candel Therapeutics.</p>

<p>In evaluating SOPH's financial performance, the <strong>Return on Invested Capital (ROIC)</strong> is a critical metric. SOPH's ROIC stands at <strong>-52.00%</strong>, which is significantly lower than its <strong>Weighted Average Cost of Capital (WACC)</strong> of <strong>8.38%</strong>. This negative ROIC indicates that SOPH is not generating enough returns to cover its cost of capital, a situation that can hinder its financial sustainability.</p>

<p>Comparing SOPH to its peers, Rapid Micro Biosystems (RPID) has an even lower ROIC of <strong>-61.04%</strong> with a WACC of <strong>8.91%</strong>, resulting in a ROIC to WACC ratio of <strong>-6.85</strong>. Singular Genomics Systems (OMIC) also shows a negative ROIC of <strong>-55.79%</strong> against a WACC of <strong>7.50%</strong>, leading to a ratio of <strong>-7.44</strong>. These figures suggest that both companies are also struggling to generate returns above their cost of capital.</p>

<p>Rallybio Corporation (RLYB) and Candel Therapeutics (CADL) present more severe cases, with ROICs of <strong>-101.22%</strong> and <strong>-215.90%</strong>, respectively. Their WACCs are <strong>4.94%</strong> and <strong>4.81%</strong>, resulting in ROIC to WACC ratios of <strong>-20.48</strong> and <strong>-44.93</strong>. These numbers highlight significant challenges in achieving capital efficiency, which is crucial for their financial health.</p>

<p>Among the peers, Absci Corporation (ABSI) has the highest ROIC to WACC ratio of <strong>-3.58</strong>, with a ROIC of <strong>-48.45%</strong> and a WACC of <strong>13.55%</strong>. Although still negative, ABSI's ratio indicates a relatively better position in managing its capital compared to its cost. This analysis underscores the importance of improving capital efficiency for these companies to ensure long-term growth and stability.</p>",NASDAQ:SOPH,https://portal.financialmodelingprep.com/positions/67cafcab3b1fda08ff03f470.jpeg,https://financialmodelingprep.com/market-news/sophia-genetics-sa-nasdaq-soph-financial-analysis,Andrew Wynn,Financial Modeling Prep
State Street Corporation's Financial Performance and Capital Utilization Compared to Peers,2025-03-06 16:00:06,"<ul>
<li><strong>State Street Corporation</strong> (<a href=""https://site.financialmodelingprep.com/financial-summary/STT"">NYSE:STT</a>) has a <strong>Return on Invested Capital (ROIC) of 0.55%</strong> and a <strong>Weighted Average Cost of Capital (WACC) of 17.31%</strong>, indicating inefficient capital utilization.</li>
<li><strong>Zions Bancorporation</strong> stands out with a <strong>ROIC of 7.30%</strong> and a <strong>WACC of 17.47%</strong>, showcasing superior capital efficiency with a ROIC to WACC ratio of <strong>0.41</strong>.</li>
<li><strong>The PNC Financial Services Group</strong> demonstrates effective capital utilization with a <strong>ROIC of 1.09%</strong> and a <strong>WACC of 13.25%</strong>, resulting in a ROIC to WACC ratio of <strong>0.08</strong>.</li>
</ul>
<p>State Street Corporation (<a href=""https://site.financialmodelingprep.com/financial-summary/STT"">NYSE:STT</a>) is a financial services company that provides investment management, research, and trading services. It operates globally, offering services to institutional investors. In the financial sector, State Street competes with companies like Northern Trust Corporation, The Bank of New York Mellon Corporation, The PNC Financial Services Group, Comerica Incorporated, and Zions Bancorporation.</p>
<p>In evaluating State Street's financial performance, the <strong>Return on Invested Capital (ROIC) versus the Weighted Average Cost of Capital (WACC)</strong> is crucial. State Street's ROIC is <strong>0.55%</strong>, while its WACC is <strong>17.31%</strong>, resulting in a ROIC to WACC ratio of <strong>0.03</strong>. This ratio indicates that State Street's returns on invested capital are not covering its cost of capital effectively.</p>
<p>Comparatively, Northern Trust Corporation has a ROIC of <strong>0.81%</strong> and a WACC of <strong>30.60%</strong>, leading to a ROIC to WACC ratio of <strong>0.02</strong>. Although Northern Trust's ROIC is higher than State Street's, its higher WACC results in a lower efficiency ratio. The Bank of New York Mellon Corporation shows a ROIC of <strong>0.79%</strong> and a WACC of <strong>23.75%</strong>, with a ROIC to WACC ratio of <strong>0.03</strong>, slightly better than State Street's.</p>
<p>The PNC Financial Services Group demonstrates a more favorable scenario with a ROIC of <strong>1.09%</strong> and a WACC of <strong>13.25%</strong>, resulting in a ROIC to WACC ratio of <strong>0.08</strong>. This suggests PNC is utilizing its capital more effectively than State Street. Comerica Incorporated, with a ROIC of <strong>0.43%</strong> and a WACC of <strong>14.89%</strong>, has a ROIC to WACC ratio of <strong>0.02</strong>, indicating similar challenges in capital utilization as State Street.</p>
<p>Zions Bancorporation stands out with a ROIC of <strong>7.30%</strong> and a WACC of <strong>17.47%</strong>, achieving a ROIC to WACC ratio of <strong>0.41</strong>. This high ratio suggests Zions is significantly more efficient in using its capital compared to State Street and its other peers, highlighting its superior capital utilization.</p>",NYSE:STT,https://portal.financialmodelingprep.com/positions/67cafe703b1fda08ff03f9f1.jpeg,https://financialmodelingprep.com/market-news/state-street-vs-peers-capital-utilization-financial-performance,Andrew Wynn,Financial Modeling Prep
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Financial Performance and Competitive Landscape,2025-03-06 16:00:05,"<ul>
<li><strong>Avadel Pharmaceuticals plc</strong> (<a href=""https://site.financialmodelingprep.com/financial-summary/AVDL"">NASDAQ:AVDL</a>) has a <strong>Return on Invested Capital (ROIC) of -36.37%</strong> and a <strong>Weighted Average Cost of Capital (WACC) of 12.52%</strong>, indicating challenges in generating returns that exceed its cost of capital.</li>
<li>Compared to its competitors, Avadel has a better ROIC to WACC ratio than Eyenovia and Clearside Biomedical, but is outperformed by Aquestive Therapeutics and Intra-Cellular Therapies in terms of capital efficiency.</li>
<li>Intra-Cellular Therapies leads the group with the highest ROIC to WACC ratio, suggesting it is closest to achieving positive returns relative to its cost of capital.</li>
</ul>

<p>Avadel Pharmaceuticals plc (<a href=""https://site.financialmodelingprep.com/financial-summary/AVDL"">NASDAQ:AVDL</a>) is a biopharmaceutical company focused on developing and commercializing innovative medicines. The company primarily targets sleep disorders, with its lead product, LUMRYZ, aimed at treating narcolepsy. Avadel operates in a competitive landscape alongside companies like Eyenovia, Aquestive Therapeutics, Clearside Biomedical, and Intra-Cellular Therapies, each with their own focus areas and product pipelines.</p>

<p>In evaluating Avadel's financial performance, the <strong>Return on Invested Capital (ROIC)</strong> and <strong>Weighted Average Cost of Capital (WACC)</strong> are key metrics. Avadel's ROIC stands at <strong>-36.37%</strong>, while its WACC is <strong>12.52%</strong>. This results in a ROIC to WACC ratio of <strong>-2.90</strong>, indicating that the company is not currently generating returns that exceed its cost of capital. This is a critical measure of how effectively Avadel is using its capital.</p>

<p>Comparatively, Eyenovia has a significantly lower ROIC of <strong>-205.42%</strong> and a WACC of <strong>11.01%</strong>, leading to a ROIC to WACC ratio of <strong>-18.65</strong>. This suggests Eyenovia is less efficient in capital utilization than Avadel. Meanwhile, Aquestive Therapeutics has a ROIC of <strong>-37.16%</strong> and a WACC of <strong>17.92%</strong>, resulting in a slightly better ROIC to WACC ratio of <strong>-2.07</strong> compared to Avadel.</p>

<p>Clearside Biomedical's ROIC is <strong>-81.71%</strong> with a WACC of <strong>17.50%</strong>, yielding a ROIC to WACC ratio of <strong>-4.67</strong>. This places Clearside below Avadel in terms of capital efficiency. Intra-Cellular Therapies, however, has the highest ROIC to WACC ratio among the peers at <strong>-1.38</strong>, with a ROIC of <strong>-10.08%</strong> and a WACC of <strong>7.29%</strong>. This indicates that Intra-Cellular Therapies is closer to achieving positive returns relative to its cost of capital, despite still being negative.</p>",NASDAQ:AVDL,https://portal.financialmodelingprep.com/positions/67cb02273b1fda08ff04044c.png,https://financialmodelingprep.com/market-news/avadel-pharmaceuticals-financial-performance-competitive-landscape,Alex Lavoie,Financial Modeling Prep
Oracle Corporation's Upcoming Earnings Report: A Detailed Analysis,2025-03-06 16:00:05,"<p>Oracle Corporation (<a href=""https://site.financialmodelingprep.com/financial-summary/ORCL"">NYSE:ORCL</a>) is a leading technology company known for its comprehensive suite of cloud applications and infrastructure services. As it prepares to release its quarterly earnings on March 10, 2025, investors are keenly watching the anticipated figures.</p>
<p>Analysts expect an <strong>earnings per share (EPS) of $1.48</strong>, reflecting a <strong>5% increase</strong> from the previous year, and revenue projections stand at approximately <strong>$14.4 billion</strong>, marking an <strong>8.1% year-over-year growth</strong>. The upcoming earnings report is crucial for Oracle, especially after the recent DeepSeek AI sell-off, which affected investor sentiment.</p>
<p>The company's <strong>price-to-earnings (P/E) ratio</strong> is <strong>36.23</strong>, indicating how the market values its earnings. Despite a slight <strong>0.1% downward revision</strong>&nbsp;in the consensus EPS estimate over the past 30 days, the anticipated growth in revenue and EPS could help restore investor confidence.</p>
<p>Oracle's financial metrics provide insight into its market valuation. The <strong>price-to-sales ratio</strong> of <strong>7.69</strong> and <strong>enterprise value to sales ratio</strong> of <strong>9.10</strong> reflect the market's perception of its revenue and sales. The <strong>enterprise value to operating cash flow ratio</strong> is <strong>24.64</strong>, showing how the market values Oracle's cash flow from operations.</p>
<p>These figures are essential for investors assessing the company's financial health and growth potential. The company's <strong>debt-to-equity ratio </strong>of <strong>6.45</strong> highlights its significant leverage, which can be a double-edged sword. While leverage can amplify returns, it also increases financial risk. Oracle's <strong>current ratio</strong> of <strong>0.81</strong> suggests a limited ability to cover short-term liabilities with short-term assets, which may be a point of concern for some investors. However, the <strong>earnings yield</strong> of <strong>2.76%</strong>&nbsp;offers a perspective on the earnings generated per dollar invested, providing a measure of potential return.</p>",NYSE:ORCL,https://portal.financialmodelingprep.com/positions/67caff643b1fda08ff03fc7d.jpeg,https://financialmodelingprep.com/market-news/oracle-corporation-earnings-preview-march-2025-analysis,Tony Dante,Financial Modeling Prep
"Cisco Systems, Inc. (NASDAQ:CSCO) - A Comprehensive Analysis",2025-03-06 14:06:14,"<p>Cisco Systems, Inc. (<a href=""https://site.financialmodelingprep.com/financial-summary/CSCO"">NASDAQ:CSCO</a>) is a leading player in the computer networking sector, known for its innovative networking hardware, software, and telecommunications equipment. The company competes with other industry players like Digi International (DGII).</p>
<p>Both Cisco and Digi are currently rated with a Zacks Rank of #2 (Buy), indicating a positive earnings outlook due to favorable analyst estimate revisions. On March 6, 2025, Piper Sandler updated its rating for Cisco to Neutral, maintaining a hold action. At that time, the stock price was <strong>$63.10</strong>.</p>
<p>Currently, the stock price is <strong>$63.05</strong>, reflecting a slight decrease of <strong>1.42%</strong> or <strong>$0.91</strong>. The stock has traded between <strong>$62.91</strong> and <strong>$64.02</strong> today, with a market capitalization of approximately <strong>$250.83 billion</strong>. Despite the Neutral rating from Piper Sandler, Cisco's Zacks Rank of #2 (Buy) suggests a strong value opportunity.</p>
<p>This rank targets companies with positive earnings estimate revision trends, indicating confidence in Cisco's improving earnings outlook. Investors may find this encouraging, as it reflects a favorable analyst sentiment towards the company's future performance. Cisco's stock has experienced fluctuations over the past year, reaching a high of <strong>$66.50</strong> and a low of <strong>$44.50</strong>. The current trading volume is <strong>10,405,959</strong> shares on the NASDAQ exchange. This level of activity indicates significant investor interest, which could be attributed to the company's strong market position and positive earnings outlook.</p>",NASDAQ:CSCO,https://portal.financialmodelingprep.com/positions/67cb01c53b1fda08ff0403b3.jpeg,https://financialmodelingprep.com/market-news/cisco-systems-nasdaq-csco-market-analysis-future-outlook,Alex Lavoie,Financial Modeling Prep
Evogene Ltd. (NASDAQ:EVGN) Earnings Report Highlights,2025-03-06 14:00:06,"<ul>
<li><strong>Earnings Per Share (EPS) of $0.06</strong> exceeded the estimated EPS, showcasing better-than-expected profitability.</li>
<li>Actual revenue of approximately <strong>$1.61 million</strong> fell short of the estimated $4 million, indicating challenges in meeting revenue expectations.</li>
<li>Significant revenue growth in 2024 to approximately <strong>$8.5 million</strong>, driven by collaborations and increased seed sales.</li>
</ul>

<p><a href=""https://site.financialmodelingprep.com/financial-summary/EVGN"">Evogene Ltd. (NASDAQ:EVGN)</a> is a leading entity in the computational biology sector, focusing on the development of innovative products across agriculture, human health, and industrial applications. The company utilizes its proprietary computational predictive biology platform to enhance product development, positioning itself against competitors like Monsanto and Syngenta.</p>

<p>On March 6, 2025, Evogene reported its earnings, revealing an <strong>EPS of $0.06</strong>, which exceeded the estimated EPS of -$0.73. This positive surprise in EPS indicates that the company managed to perform better than expected in terms of profitability. However, the actual revenue of approximately <strong>$1.61 million</strong> fell short of the estimated $4 million, suggesting challenges in meeting revenue expectations.</p>

<p>During the Q4 2024 earnings conference call, key figures such as Ofer Haviv, the President and CEO, and Yaron Eldad, the CFO, discussed the company's financial performance. Despite the revenue shortfall, Evogene's total revenues for 2024 increased significantly to approximately <strong>$8.5 million</strong>, up from $5.6 million in 2023. This growth was largely driven by AgPlenus' collaboration with Bayer and increased seed sales from Casterra.</p>

<p>Evogene's financial metrics reveal some challenges. The company has a negative price-to-earnings (P/E) ratio of approximately <strong>-0.34</strong>, indicating a lack of profitability. The price-to-sales ratio is about <strong>0.99</strong>, suggesting the stock is valued close to its sales per share. Additionally, the enterprise value to sales ratio is approximately <strong>0.95</strong>, reflecting a similar valuation to its price-to-sales ratio.</p>

<p>The company's financial health is further highlighted by its negative enterprise value to operating cash flow ratio of around <strong>-0.35</strong>, indicating difficulties in generating positive cash flow from operations. The negative earnings yield of approximately <strong>-2.92%</strong> and a negative debt-to-equity ratio of about <strong>-2.53</strong> suggest higher liabilities compared to equity. However, the current ratio of approximately <strong>1.09</strong> indicates a reasonable level of short-term financial health, with current assets slightly exceeding current liabilities.</p>",NASDAQ:EVGN,https://portal.financialmodelingprep.com/positions/67cb02cf3b1fda08ff040590.jpeg,https://financialmodelingprep.com/market-news/evogene-ltd-evgn-earnings-report-highlights,Alex Lavoie,Financial Modeling Prep
Northrop Grumman Corporation (NYSE:NOC) Recognizes Trident Systems with Supplier Excellence Award,2025-03-06 14:00:05,"<ul>
<li>Northrop Grumman Corporation (<a href=""https://site.financialmodelingprep.com/financial-summary/NOC"">NYSE:NOC</a>) awards Trident Systems for its contributions to national security technologies, reflecting strategic and financial stability.</li>
<li>Trident Systems' innovative and cost-effective solutions align with Northrop Grumman's focus on advanced weapons and defense systems, supported by strong financial ratios such as a <strong>P/E ratio of 16.42</strong> and a <strong>price-to-sales ratio of 1.66</strong>.</li>
<li>Northrop Grumman's financial health is highlighted by a <strong>dividend announcement of $2.06</strong>, an <strong>earnings yield of 6.09%</strong>, and a <strong>current ratio of 1.01</strong>, indicating a commitment to shareholder returns and operational efficiency.</li>
</ul>
<p>Northrop Grumman Corporation (<a href=""https://site.financialmodelingprep.com/financial-summary/NOC"">NYSE:NOC</a>) is a leading global aerospace and defense technology company. It provides innovative systems, products, and solutions in autonomous systems, cyber, C4ISR, space, strike, and logistics and modernization to customers worldwide. The company has recognized Trident Systems, a LightRidge Solutions Company, with a Supplier Excellence Award, highlighting Trident's significant contributions to national security technologies.</p>
<p>Trident Systems has been acknowledged for its strategic excellence, offering innovative and cost-effective military solutions. This recognition aligns with Northrop Grumman's financial stability, as evidenced by its <strong>price-to-earnings (P/E) ratio of 16.42</strong>, which reflects investor confidence in its earnings potential. Trident's commitment to delivering purpose-built solutions complements Northrop Grumman's focus on providing next-generation advantages in advanced weapons and defense systems.</p>
<p>Trident's open architecture systems, which enhance integration and reduce costs, are crucial for Northrop Grumman's operational excellence. This is supported by Northrop Grumman's <strong>price-to-sales ratio of 1.66</strong>, indicating efficient revenue generation. Trident's flexibility and interoperability ensure timely delivery of reliable flight units, aligning with Northrop Grumman's <strong>enterprise value to sales ratio of 1.59</strong>, reflecting its total value in relation to sales.</p>
<p>LightRidge Solutions, Trident's parent company, offers advanced capabilities for national security, including space payloads and laser communications. These capabilities support Northrop Grumman's strategic goals, as highlighted by its <strong>low debt-to-equity ratio of 0.12</strong>, indicating a conservative capital structure. This financial prudence ensures the company can invest in innovative technologies while maintaining financial stability.</p>
<p>Northrop Grumman's recent dividend announcement of <strong>$2.06</strong>, with a record date of March 3, 2025, and payment on March 19, 2025, underscores its commitment to shareholder returns. The company's <strong>earnings yield of 6.09%</strong> provides a solid return on investment, while its<strong> current ratio of 1.01</strong>&nbsp;suggests a balanced level of current assets to cover liabilities, ensuring financial health and operational efficiency.</p>",NYSE:NOC,https://portal.financialmodelingprep.com/positions/67cb04a73b1fda08ff040ab8.jpeg,https://financialmodelingprep.com/market-news/northrop-grumman-awards-trident-systems-supplier-excellence,Andrew Wynn,Financial Modeling Prep
